Poster Presentation 5th Modern Solid Phase Peptide Synthesis Symposium 2015

Development of superior fluorescently labelled peptides for studying Y receptor biology (#55)

Mengjie Liu 1 , Simon J Mountford 1 , Lei Zhang 2 , Rachel Richardson 3 , Marleen Groenen 3 , Herbert Herzog 2 , Nicholas Holliday 3 , Philip E Thompson 1
  1. Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
  2. Neuroscience Research Program, Garvan Institute of Medical Research, St Vincent’s Hospital, Darlinghurst, NSW, Australia
  3. School of Life Sciences, Queen's Medical Centre, Nottingham, UK

Neuropeptide Y (NPY) is a peptidic neurotransmitter abundantly expressed in human physiological systems. It elicits many physiological and pathophysiological functions by activating Y receptors. Our work has applied a variety of synthetic approaches to develop peptide conjugates that possess affinity to the Y1 and Y4 receptor subtypes. These conjugates may offer great potential for studying fundamental features of Y receptor localisation, functions and leading therapeutic targeting.

Using modern peptide synthesis and conjugation strategies, we have identified two groups of fluorescently labelled peptide conjugates originated from the C-terminal fragment of NPY. The first group contains peptides derived from the monomeric BVD-15 peptide scaffold that show strong Y1 receptor affinity. The second group includes peptides derived from the dimeric, dicarba-bridged BVD-74D scaffold that have potent activity at Y4 receptors. These ligands show a range of properties such as single and dual subtype selectivity, agonism and antagonism – that allow them to be used as pharmacological tools for studying Y receptors.